AbbVie (ABBV.US) Upadacitinib Extended-Release Tablets new indication proposed for priority review

LootboxPhobia · 2026-03-13T12:27:42+00:00

AbbVie's extended-release upadacitinib for the new indication of non-segmental vitiligo has been included in priority review, applicable to adults and adolescents aged 12 and above. The drug is expected to achieve global sales of $8.304 billion by 2025.

LootboxPhobia

2026-03-13 12:27:42

Abstract generation in progress

According to Cailian Press APP, on March 12, the CDE official website showed that AbbVie’s (ABBV.US) Upadacitinib Extended-Release Tablets is proposed to be included in priority review for a new indication, intended for the treatment of non-segmental vitiligo in adults and adolescents aged 12 and above. Upadacitinib is a selective JAK inhibitor and a key product under AbbVie, with global sales of $8.304 billion in 2025 (+39.07%).

Screenshot source: CDE official website

The application for priority review concerns a new indication: non-segmental vitiligo in adults and adolescents aged 12 and above. Regarding this indication, in February this year, AbbVie announced that it had submitted applications to the U.S. FDA and the European EMA for Upadacitinib to treat non-segmental vitiligo (NSV) in adults and adolescents.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.